AR011592A1 - METHOD OF CREATION, OR MAINTENANCE, OR TO INDUCE AN IMMUNE PROTECTIVE OR ADAPTIVE RESPONSE TO AN HIV VIRUS IN A GUEST - Google Patents

METHOD OF CREATION, OR MAINTENANCE, OR TO INDUCE AN IMMUNE PROTECTIVE OR ADAPTIVE RESPONSE TO AN HIV VIRUS IN A GUEST

Info

Publication number
AR011592A1
AR011592A1 ARP980100406A ARP980100406A AR011592A1 AR 011592 A1 AR011592 A1 AR 011592A1 AR P980100406 A ARP980100406 A AR P980100406A AR P980100406 A ARP980100406 A AR P980100406A AR 011592 A1 AR011592 A1 AR 011592A1
Authority
AR
Argentina
Prior art keywords
guest
induce
creation
maintenance
hiv virus
Prior art date
Application number
ARP980100406A
Other languages
Spanish (es)
Original Assignee
Univ Tulane
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tulane filed Critical Univ Tulane
Publication of AR011592A1 publication Critical patent/AR011592A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Se proponen métodos y composiciones para el uso de una forma mutante nueva de E.coli lábil al calor enterotoxina que perdio su toxicidad peroretuvo su actividad inmunologica. Esta enterotoxina se usa en combinacion con un antígeno no relacionado para lograr una respuesta inmune aumentada a dichoantígeno cuando se administra como parte de una preparacion de vacuna.Methods and compositions are proposed for the use of a novel mutant form of heat-labile E. coli enterotoxin that lost its toxicity but retained its immunological activity. This enterotoxin is used in combination with an unrelated antigen to achieve an increased immune response to said antigen when administered as part of a vaccine preparation.

ARP980100406A 1997-01-29 1998-01-29 METHOD OF CREATION, OR MAINTENANCE, OR TO INDUCE AN IMMUNE PROTECTIVE OR ADAPTIVE RESPONSE TO AN HIV VIRUS IN A GUEST AR011592A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79069197A 1997-01-29 1997-01-29

Publications (1)

Publication Number Publication Date
AR011592A1 true AR011592A1 (en) 2000-08-30

Family

ID=25151481

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980100406A AR011592A1 (en) 1997-01-29 1998-01-29 METHOD OF CREATION, OR MAINTENANCE, OR TO INDUCE AN IMMUNE PROTECTIVE OR ADAPTIVE RESPONSE TO AN HIV VIRUS IN A GUEST

Country Status (5)

Country Link
AR (1) AR011592A1 (en)
AU (1) AU6044598A (en)
CO (1) CO4810235A1 (en)
WO (1) WO1998032461A1 (en)
ZA (1) ZA98738B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7384640B1 (en) 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
JP2004535187A (en) 2001-06-07 2004-11-25 ワイス・ホールデイングス・コーポレーシヨン Mutant forms of cholera holotoxin as adjuvants
KR100877258B1 (en) 2001-06-07 2009-01-12 와이어쓰 홀딩스 코포레이션 Mutant forms of cholera holotoxin as an adjuvant

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2849632B2 (en) * 1988-04-08 1999-01-20 社団法人北里研究所 Vaccine preparation
IT1253009B (en) * 1991-12-31 1995-07-10 Sclavo Ricerca S R L DETOXIFIED IMMUNOGENIC MUTANTS OF COLERIC TOXIN AND TOXIN LT, THEIR PREPARATION AND USE FOR THE PREPARATION OF VACCINES

Also Published As

Publication number Publication date
ZA98738B (en) 1998-08-04
WO1998032461A1 (en) 1998-07-30
CO4810235A1 (en) 1999-06-30
AU6044598A (en) 1998-08-18

Similar Documents

Publication Publication Date Title
FI970799A (en) Mutant enterotoxin effective as a non-toxic oral adjuvant
DE60045668D1 (en) Influenza virus vaccine composition
AR025750A1 (en) VACCINES
MX9401225A (en) VACCINE COMPOSITION TO PREVENT INFECTION WITH INFLUENZA IN HUMANS AND METHOD FOR ITS PREPARATION.
ES2186809T3 (en) COMPOSITIONS OF VACCINES FOR INTRANASAL ADMINISTRATION, UNDERSTANDING CHITOSANA AND ITS USE.
MX9201245A (en) NEW VACCINE FORMULATION TO TREAT INFECTIONS CAUSED BY SIMPLE HERPES VIRUS.
DK0814836T3 (en) vaccine adjuvants
NO20015073L (en) vaccinations
AR035586A1 (en) COMPOSITION OF VACCINE, EQUIPMENT, METHODS TO INCREASE THE IMMUNE RESPONSE, USE OF A DERIVATIVE OF 1H-IMIDAZO (4,5-C) QUINOLIN-4-AMINA IN THE MANUFACTURE OF A MEDICINAL PRODUCT, AND COMBINATION OF COMPONENTS FOR SEPARATE, SEQUENTIAL ADMINISTRATION OR CONCOMITANT FOR USE IN DNA VACCINATION
ES2113882T3 (en) ORAL VACCINE INCLUDING AN ANTIGEN ASSOCIATED SURFACE WITH Erythrocytes.
IS5329A (en) Antigen transport system where monoglyceride or diglyceride derivatives are adjuvant
DE60144240D1 (en) COMPOSITION WITH IMMUNOGENIC MICROPARTICLES
AU4622693A (en) Potentiation of immunogenic response
AR069722A1 (en) VACCINE AGAINST ESCHERICHIA COLI ENTEROHEMORRAGICA
NO20015074D0 (en) New compositions
ES2530510T3 (en) Synthetic peptide constructs for the diagnosis and treatment of periodontitis associated with Porphyromonas gingivalis
BR9815404A (en) Adjuvant composition to stimulate an efficient immune response to an antigenic substance, vaccine for administration to an animal, process to stimulate an effective immune response in an animal to an antigenic substance, and use of the adjuvant composition.
AR011592A1 (en) METHOD OF CREATION, OR MAINTENANCE, OR TO INDUCE AN IMMUNE PROTECTIVE OR ADAPTIVE RESPONSE TO AN HIV VIRUS IN A GUEST
ES2079851T3 (en) USE OF IL-4 TO IMPROVE THE IMMUNE RESPONSE AGAINST IMMUNOGEN IN VACCINES.
ES2046246T3 (en) THERAPEUTIC COMPOSITION TO FIGHT AIDS.
AR012896A1 (en) HELICOBACTER PYLORI FLGE POLYPEPTIDE, VACCINE COMPOSITION, USE OF SUCH POLYPEPTIDE FOR THE MANUFACTURE OF COMPOSITIONS, INVITRO DIAGNOSTIC METHOD AND DIAGNOSTIC KIT FOR THE DETECTION OF HELICOBACTER PYLORI INFECTION
HU0102823D0 (en) A broad spectrum infectious bursal disease virus vaccine
BR0013574A (en) Old Moraxella Vaccine
AR037908A1 (en) A BIOMASS IN AVIAN EMBRYO PARTICLES FOR THE PRODUCTION OF VIRUS ANTIGENS
RU96116250A (en) STRAIN PESTIVIRUS USED TO MAKE THE LAPINIZED VACCINE VACCINE AGAINST CLASSIC PIG PLANE